Wave Life Sciences Ltd. - WVE STOCK NEWS

IMPACT

SENTIMENT

04/19/2022 08:30 AM

WVE : Nasdaq

Wave Life Sciences to Present at Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

IMPACT

SENTIMENT

04/04/2022 07:30 AM

WVE : Nasdaq

Wave Life Sciences Announces Positive Update to Ongoing Phase 1b/2a FOCUS-C9 Study Driven by Potent, Durable Reductions of Poly(GP) with Low, Single Doses of WVE-004

IMPACT

SENTIMENT

03/21/2022 08:30 AM

WVE : Nasdaq

Wave Life Sciences to Present at Stifel 2022 CNS Days

IMPACT

SENTIMENT

03/15/2022 08:30 AM

WVE : Nasdaq

Wave Life Sciences to Highlight RNA Base Editing Modality and Alpha-1 Antitrypsin Deficiency Program at Upcoming Scientific and Industry Meetings

IMPACT

SENTIMENT

03/07/2022 11:14 AM

WVE : Nasdaq

Wave Life Sciences Announces Nature Biotechnology Publication Highlighting First RNA Base Editing in Non-Human Primates Using an Endogenous Enzyme

IMPACT

SENTIMENT

03/03/2022 07:30 AM

WVE : Nasdaq

Wave Life Sciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

IMPACT

SENTIMENT

02/24/2022 08:30 AM

WVE : Nasdaq

Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2021 Financial Results on March 3, 2022

IMPACT

SENTIMENT

02/09/2022 08:30 AM

WVE : Nasdaq

Wave Life Sciences to Present at the Virtual 11th Annual SVB Leerink Global Healthcare Conference 2022

IMPACT

SENTIMENT

02/02/2022 04:05 PM

WVE : Nasdaq

Wave Life Sciences Announces Two Papers in the Journal Nucleic Acids Research Describing How PN Backbone Chemistry Modifications Enhance the Pharmacological Effects of Oligonucleotides

IMPACT

SENTIMENT

01/25/2022 11:07 AM

WVE : Nasdaq

ADDF and AFTD Partner to Support Wave Life Sciences' FTD and ALS Clinical Program

Wave Life Sciences Ltd.

Nasdaq:WVE

WVE Rankings

#3558 Ranked by Market Cap

N/A Ranked by Dividends

WVE Stock Data

Industry Pharmaceutical Preparation Manufacturing

Sector Manufacturing

Website Link

Country Singapore

City 7 Straits View

About WVE

wave life sciences ltd. (nasdaq: wve) is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering new treatment options for patients. given the unique versatility of its chemistry platform, wave’s pipeline spans multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded rnai.